[Market Focus] SCL Science Surges 26% on News of Internal Hemostatic Product Sales Expansion

SCL Science, the medical device subsidiary of SCL Group, is showing strong performance in early trading.

As of 9:06 a.m. on May 30, SCL Science was trading at 10,090 won, up 26.28% (2,100 won) from the previous day.

The surge in share price was driven by news that the health insurance reimbursement for 'Inoseal Plus DL', an internal hemostatic product developed by SCL Science, has been finalized.

Inoseal Plus DL is a Class 4 absorbable internal hemostatic product that immediately reacts with various proteins in the blood to form a physical hemostatic barrier, sealing bleeding sites. It is a high-performance product that can be used for patients with blood coagulation disorders and has been priced at a level approximately 10 times higher than existing external products. With demand rapidly expanding in complex and precise surgical environments, there are expectations that this will have a positive impact on the company's growth and profitability.

Previously, SCL Science recorded sales of 2.3 billion won in the first quarter, a 100% increase compared to the same period last year. Performance improvements were driven by new business areas such as digital platforms and biologistics. SCL Science expects this positive trend to continue from the second quarter onward, as the results of SCL Healthcare, which became a wholly owned subsidiary at the end of March, are now being fully reflected.